- Home
- AR vs ABVX Comparison
AR vs ABVX Comparison
Compare AR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AR | ABVX |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 9.7B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | AR | ABVX |
|---|---|---|
| Price | $38.62 | $110.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 13 |
| Target Price | $47.13 | ★ $131.31 |
| AVG Volume (30 Days) | ★ 5.3M | 785.9K |
| Earning Date | 04-29-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $5,275,823,000.00 | N/A |
| Revenue This Year | $29.74 | $52.14 |
| Revenue Next Year | $5.07 | $4,132.27 |
| P/E Ratio | $18.92 | ★ N/A |
| Revenue Growth | ★ 21.97 | N/A |
| 52 Week Low | $29.10 | $5.59 |
| 52 Week High | $45.75 | $148.83 |
Technical Indicators
Market Signals| Indicator | AR | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 42.71 |
| Support Level | $32.27 | $107.55 |
| Resistance Level | $45.75 | $129.84 |
| Average True Range (ATR) | 1.18 | 5.18 |
| MACD | 0.02 | -1.02 |
| Stochastic Oscillator | 76.68 | 2.32 |
Price Performance
Historical ComparisonAbout AR Antero Resources Corporation
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2025, the company reported proven reserves of 19.1 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,442 million cubic feet of equivalent per day in 2025 at a ratio of 35% liquids and 65% natural gas.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.